TETRA Technologies logo

TETRA Technologies

TTI | NYSE
Chart Builder DCF Calculator
$6.20
-$0.19 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$6.20
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:01 PM ET
-2.97%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
42.5
Fundamentals Average
Market Sentiment Bullish
Moat Narrow
Sector Rank #194/294 (Top 66%)

Key Statistics

Market Data

Market Cap $920.27M
1D Range
6.14 6.37
52W Range
5.15 12.32

Valuation (TTM)

PE 87.82
PB 2.22
EV/EBITDA 12.96

Valuation (NTM)

Forward PE 25.56
Forward PEG 9.07
Price Target $10.00
Loading financial charts...

Profile

TETRA Technologies, Inc. (TTI) is a diversified enterprise that delivers a range of services to the oil and gas industry. The company organizes its operations into two primary divisions: Completion Fl...

Sector Energy
Employees 1,400
IPO Date Apr 3, 1990
Fiscal Year January - December

Latest News

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript

3 months ago · seekingalpha.com

Tvardi Therapeutics, Inc. (TVRD) Discusses TTI-109 Development Program and Data in Ulcerative Colitis Transcript
Tetra Technologies (TTI) Reports Q2 Earnings: What Key Metrics Have to Say

3 months ago · zacks.com

Tetra Technologies (TTI) Reports Q2 Earnings: What Key Metrics Have to Say
TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

TETRA Technologies, Inc. (TTI) Q2 2026 Earnings Call Transcript
Tetra Technologies (TTI) Q2 Earnings Meet Estimates

4 months ago · zacks.com

Tetra Technologies (TTI) Q2 Earnings Meet Estimates
Compared to Estimates, Tetra Technologies (TTI) Q2 Earnings: A Look at Key Metrics

4 months ago · zacks.com

Compared to Estimates, Tetra Technologies (TTI) Q2 Earnings: A Look at Key Metrics
TETRA TECHNOLOGIES, INC. REPORTS STRONG SECOND-QUARTER 2026 RESULTS

4 months ago · prnewswire.com

TETRA TECHNOLOGIES, INC. REPORTS STRONG SECOND-QUARTER 2026 RESULTS
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

4 months ago · globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
Tetra Technologies (TTI) to Report Q2 Results: What to Know Ahead of the Release

4 months ago · zacks.com

Tetra Technologies (TTI) to Report Q2 Results: What to Know Ahead of the Release
TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR SECOND QUARTER 2026 EARNINGS CONFERENCE CALL

4 months ago · prnewswire.com

TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR SECOND QUARTER 2026 EARNINGS CONFERENCE CALL
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

4 months ago · newsfilecorp.com

Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

Earnings

Latest Earnings
Nov 2, 2026
EPS
$0.06
Beat +25.00%
REV
$167.95M
Beat +7.08%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
3
Consensus
Buy
Price Target
$10.00
Upside
+61.29%
Buy (3)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.